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Abstract
Human genetic and animal studies have implicated the costimulatory molecule CD40 in the
development of multiple sclerosis (MS). We investigated the cell specific gene and protein
expression variation controlled by the CD40 genetic variant(s) associated with MS, i.e. the
T-allele at rs1883832. Previously we had shown that the risk allele is expressed at a lower
level in whole blood, especially in people with MS. Here, we have defined the immune cell
subsets responsible for genotype and disease effects on CD40 expression at the mRNA
and protein level. In cell subsets in which CD40 is most highly expressed, B lymphocytes
and dendritic cells, the MS-associated risk variant is associated with reduced CD40 cell-sur-
face protein expression. In monocytes and dendritic cells, the risk allele additionally reduces
the ratio of expression of full-length versus truncated CD40 mRNA, the latter encoding se-
creted CD40. We additionally show that MS patients, regardless of genotype, express sig-
nificantly lower levels of CD40 cell-surface protein compared to unaffected controls in B
lymphocytes. Thus, both genotype-dependent and independent down-regulation of cell-sur-
face CD40 is a feature of MS. Lower expression of a co-stimulator of T cell activation,
CD40, is therefore associated with increased MS risk despite the same CD40 variant being
associated with reduced risk of other inflammatory autoimmune diseases. Our results high-
light the complexity and likely individuality of autoimmune pathogenesis, and could be con-
sistent with antiviral and/or immunoregulatory functions of CD40 playing an important role in
protection from MS.
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Introduction
The CD40 gene has been previously identified as a risk gene for multiple sclerosis (MS) [1–4]
and other autoimmune diseases, including Graves’ disease (GD) [5–8], rheumatoid arthritis
(RA) [9–12], systemic lupus erythematosus (SLE) [13] and Crohn’s disease (CD) [3]. CD40 is
an important co-stimulatory molecule expressed on the surface of a variety of antigen present-
ing cells (APCs) including dendritic cells (DCs) and B-lymphocytes, as well as cells of the in-
nate immune system such as macrophages and microglia. CD40 has previously been shown to
play a role in the development of animal models of autoimmune demyelinating disease. Deple-
tion by antagonistic antibodies [14–16] or ablation (gene knock-out) [17] of CD40 expression
results in amelioration of disease, highlighting the importance of the secondary activation sig-
nal in these inflammatory models. More recently, over-expression of CD40 in the thyroid has
been shown to lead to spontaneous induction of hyperthyroidism in a murine model [18].
While GD and RA are associated with the major allele at rs1883832 (C) associated with in-
creased CD40 expression [5,6] and therefore might be predicted to enhance a pro-inflammatory
environment/response [19], the risk allele for MS at rs1883832 (T, minor allele) is associated
with reduced CD40 expression [1,20]. Although there are many SNPs in linkage disequilibrium
(LD) with rs1883832, it is possible that rs1883832 itself mediates the functional effects of this
LD block. It is located at -1bp of the transcription start site (TSS) within the Kozak consensus se-
quence, in which the major C allele has been shown to lead to enhanced efficiency of translation
of the corresponding gene transcript [5,6]. However it is entirely possible that other SNPs in the
LD block may be contributing to or causing the functional effect driving association with disease
susceptibility. In addition, the effects of individual SNPs on expression of CD40 may, as for
other immune cell genes, be highly dependent on context (i.e. inflammation) and cell subset.
Previous studies have suggested that CD40 expression is increased at the mRNA level in pe-
ripheral blood mononuclear cells (PBMC) in MS compared to healthy/non-MS controls [21],
but is not different in cultured B lymphocytes or monocytes at the protein level [22]. However,
these studies involved small cohorts of varying disease duration and disease course (including
secondary progressive MS and primary progressive MS), and/or subjects concurrently treated
with disease-modifying therapies, all of which could potentially effect CD40 expression.
In this study, we used a relatively large cohort of untreated MS patients and unaffected con-
trols to investigate the effect of genotype on expression of peripheral blood mononuclear cell
types that produce the highest levels of CD40: B lymphocytes and monocytes. As other antigen
presenting cells (APCs) are rare in blood, but the APCs from secondary lymphoid organs and
tissues have the highest expression of CD40 of all subsets analysed in published databases
(www.immgen.org, www.biogps.org), we also used in vitro differentiation of monocytes to pro-
duce dendritic cells representative of these cell types. Further, we examined the effect of disease
on CD40 expression in B-lymphocytes and monocytes freshly isolated from the peripheral
blood of MS patients with relapsing-remitting MS (RRMS) compared to age- and sex-matched
healthy controls. Our findings implicate lowered cell-surface CD40 levels in the development
of MS, and should lead to further mechanistic investigations with potential
therapeutic implications.
Materials and Methods
Subject recruitment and demographics
Whole blood samples were collected between 8am and 1pm and processed within 3 hours for
the isolation of peripheral blood mononuclear cells (PBMCs; EDTA tubes); or stored at -20 de-
grees for whole-blood RNA (PAXgene tubes).
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MS patients were recruited according to the following criteria:—definite relapsing-remitting
MS (RRMS) according to McDonald criteria or Clinically Isolated Syndrome (CIS), aged be-
tween and inclusive of 18–65 years, not currently on immunomodulatory therapy for MS, or
none within in the last three months and no other concurrent autoimmune disease. In our co-
hort, MS patients were between the ages of 21 and 54 years (38.4± 7.7). The mean number of
years from diagnosis at the time of sample collection was 6.0 ± 7.0. Neurological outcome was
assessed using the Kurtzke Expanded Disability Status Scale (EDSS). The median EDSS was 2.0
(mean EDSS 1.9 ± 1.6). There were 18 females and 3 males within our MS cohort. Unaffected
controls were aged between and inclusive of 18–65 years of age and had no personal history of
neurological disease or autoimmune disease. Two independent healthy control cohorts were
used. Cohort 1 was composed of 56 females and 28 males, aged 37.46 (± 10.1) and cohort 2: 32
females and 17 males (entirety or subsection of cohort 2 used in figures as described). All MS
patients and healthy controls recruited for this study were Caucasian.
Ethics Statement
Ethical approval for this project was obtained from the Eastern Health Research Ethics Com-
mittee (Melbourne) and the Western Sydney Local Health District Human Ethics Committee.
All participants provided written consent.
Cell subset purification
Immune cell subsets were purified from PBMCs isolated fromMS patients and controls by ei-
ther Ficoll (GE Healthcare) or Histopaque (Invitrogen) density gradient separation. CD4, CD8,
CD4+CD45RO+ and CD4+CD45RA+ T cells, T regulatory cells (Tregs) (CD4+CD25hi), B
lymphocytes (CD19+) NK cells (CD3-CD56+), monocytes (CD14+), plasmacytoid dendritic
cells (CD303+CD304+CD123+CD11c-) and myeloid dendritic cells (CD19+CD1c-hi) were
purified using magnetic bead separation as previously described [23]. For monocyte subsets, a
monocyte enrichment kit (StemCells) was used prior to CD14 purification as per the manufac-
turers’ instructions (Human CD14 Microbeads, Miltenyi Biotec, Germany). Th1, Th2 and
Th17 subsets were differentiated in vitro from CD4+CD45RA+ as previously described [24].
DC1 and DC2s were generated in vitro from monocytes by sequential incubation with IL-4
and GMCSF, LPS and either IFNγ (DC1) or IFNβ (DC2) as previously described [23]. Purified
subsets were stored in RLT buffer (Qiagen) or Cells-to-signal Buffer (Ambion) for subsequent
RNA extraction. Purity of the cellular subsets was determined by flow cytometry.
Flow cytometric analysis
Fresh PBMC fromMS patients and healthy controls were analysed by flow cytometry using
flow cytometry antibodies purchased fromMiltenyi Biotec (Germany), including CD14-PE
(TUK4) and CD16-FITC (VEP13) for monocytes and CD19-FITC (LT19), IgG-PE (IS11-
3B2.2.3), IgD-PE (IgD26), CD27-PECy5 (M-T271), CD38-PE (IB6), and CD24-biotin (32D12/
anti-biotin-PerCP for B lymphocyte subsets. Regulatory B cells were identified as
CD19+CD38hiCD24hi using CD19-FITC, CD38-PE and CD24-biotin/antibiotin-PerCp anti-
bodies as described by the Mauri laboratory [25,26]. CD40 expression was determined in
PBMCs or purified/cultured subsets by comparison of CD40-APC (HB14) or CD40-PE
(HB14) to an isotype control (Mouse IgG1 clone IS5-21F5). Labelled cells were analysed using
a CyAn ADP analyzer (Beckman Coulter) and the data analysed using WEASEL v3.0.
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Genotyping and gene expression of CD40
DNA was extracted from whole blood as previously described [1]. DNA was genotyped for
rs1883832 using the Taqman SNP genotyping assay C_11655119 (Applied Biosystems), or by
restriction fragment length polymorphism: PCR amplification using oligonucleotides
5’- ACAGCAAGATGCGTCCCTAAAC- 3’ and 5’- CTTCCCTTTCCTTCTCATTCCC- 3’
followed by enzyme digestion with Nco1 (Promega), generating products of 114 bp and 226 bp
for the C allele and 340 bp for the T allele at rs1883832.
RNA was extracted from purified cells using the RNeasy Mini Kit (Qiagen) including
DNAse treatment. RNA from whole blood was collected using PAXgene blood RNA tubes
(PreAnalytiX, Switzerland) and total mRNA extracted using the PAXgene Blood RNA Kit
(Qiagen, Germany). Total expression of CD40 was determined by SYBR green qRT-PCR
using the following primers- forward: 5’-GCAGGGGAGTCAGCAGA-3’; reverse:
5’-TTCCTTCCCTTT CCTTCTCA-3’; and the housekeeping gene GAPDH as previously de-
scribed [20], or by next generation mRNA sequencing (RNA-Seq) analysis as previously de-
scribed [27]. The percentage of CD40 transcript encoding the full-length protein (FL) was
determined by PCR amplification of a cDNA region spanning CD40 exon 4 to exon 10
using primers:—forward 5’-CAGACACCATCTGCACCTGT-3’ and reverse,
5’-AATTGATCTCCTGGGGT TCC-3’. Molarity of the largest splice form (~400bp, encoding
the full-length isoform) as a proportion of all isoforms expressed was determined by electro-
phoresis and UV detection (Bioanalyzer, Agilent Technologies) as previously described [24].
The expression level of CD40 isoforms was determined for a series of immune cell subsets
using RNAseq (annotated using Ensembl build GRCh37.62) as previously described [23].
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5. Comparisons between groups were
made by unpaired t-test or Mann-Whitney U test as appropriate. Box and whisker plots depict
maximum and minimum values, median and interquartile range.
Results
In peripheral blood immune cells, B-lymphocytes express the highest
level of CD40 mRNA and protein
In our earlier work [20] we demonstrated that CD40 mRNA expression was genotype depen-
dent in whole blood. Here we compared expression in cell subsets purified from blood to con-
firm the likely source of these differences in mRNA expression. As expected, of the common
cell subsets found in blood, B-lymphocytes have the highest level of CD40 mRNA, with mono-
cytes and dendritic cells also contributing (Fig 1). In an RNAseq analysis of immune cell sub-
sets we previously conducted [28], several mRNA isoforms were identified in key subsets of
immune cells, including transcript encoding the full length protein (dominant) and those lack-
ing exon 5 and/or exon 6 that encode for the transmembrane region, resulting in the transla-
tion of soluble CD40 protein.
Expression of the CD40 MS risk allele correlates with reduced CD40
levels on B-cells
B-lymphocytes from healthy controls and MS patients were analysed ex vivo for expression of
surface CD40 protein using flow cytometry. B-lymphocytes were defined by forward and
side scatter (FSC/SSC) and expression of CD19 on the cell surface, and B-lymphocyte sub-
populations were defined by the presence or absence of the surface markers IgD and CD27.
CD40 and Multiple Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0127080 June 11, 2015 4 / 14
These were analysed for CD40 expression compared to an isotype control (Fig 2A). Naïve B
cells expressed significantly more CD40 on the cell surface compared to classical memory, IgM
memory B and regulatory B lymphocyte subsets (Fig 2B). Total B-lymphocytes showed a geno-
type-dependent reduction in the surface expression of CD40 (Fig 2C); with homozygous CC
individuals (n = 49) expressing 30% more total CD40 on the cell surface compared to CT
(n = 27; p = 0.0113) and TT (n = 10; p = 0.0216) individuals. The surface expression of CD40
on naïve B cells (CD19+IgD+CD27-) was not significantly associated with genotype (Fig 2D;
CC vs. CT p = 0.1715, CC vs. TT p = 0.0706), while classical memory B cells (Fig 2E, CD19+-
IgD-CD27+) demonstrated a trend towards a genotype-dependent CD40 expression profile
(CC vs. CT p = 0.0515; CC vs. TT p = 0.0571). No significant genotype-dependent expression
effects were observed in total B cells (Fig 2F; CC vs. CT p = 0.2511; CC vs. TT p = 0.3924)),
naïve B cells (Fig 2G; CC vs. CT p = 0.5701, CC vs. TT p = 0.1271)) or classical memory B cells
(Fig 2H; CC vs. CT p = 0.2511, CC vs. TT p = 0.3924) isolated from MS patients. In this study,
the genotype effect on CD40 mRNA expression measured in whole blood by RNA-Seq did not
reach significance (data not shown).
CD40 is under expressed on MS patient B-lymphocytes independent of
the CD40 risk allele effect
Comparison of B lymphocyte expression of CD40 in MS patients failed to show a significant ef-
fect of genotype on surface CD40 expression levels in total B lymphocytes (Fig 2F), naïve B
lymphocytes (Fig 2G) or classical memory B lymphocytes (Fig 2H). However, comparison of
cell surface CD40 expression on B-lymphocytes between healthy controls and MS patients (Fig
3) showed that CD40 expression was significantly lower in MS patients compared to healthy
Fig 1. CD40mRNA expression in peripheral blood immune cell subsets.CD40 mRNA expression was
determined by RT-PCR in freshly purified immune cell subsets or in vitro differentiated subsets (Th1, Th2,
Th17; differentiated from fresh CD4CD45RA) from healthy controls (n = 3, or n = 2 for pDC).
doi:10.1371/journal.pone.0127080.g001
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controls in all CD19+ B-lymphocytes (Fig 3A; p<0.0001), as well as in the naïve B lympho-
cytes\ (Fig 3C; p<0.0001), classical memory B-lymphocyte (Fig 3D; p = 0.0001) and IgM
memory B lymphocyte subsets (Fig 3E; p = 0.0004). A subset comparison of patients and unaf-
fected controls homozygous for the rs1883832 C allele (CC) also demonstrated a significant de-
crease in CD40 expression on the total B—lymphocytes of MS patients compared to controls
(Fig 3B; p<0.0001) The relative proportions of total B-lymphocytes and subsets as a percent-
age of total white cells were not affected by genotype or phenotype (data not shown).
CD40 is expressed at significantly lower levels in “classical”monocytes
compared to “intermediate” and “non-classical”monocytes
Monocytes fromMS patients and healthy controls defined by FSC/SSC profiles and CD14 posi-
tivity were analysed for expression of CD40. Classical monocytes were defined as CD14
+CD16-, intermediate monocytes as CD14+CD16+, and non-classical monocytes as CD14low,
CD16++ (Fig 4A). The proportion of monocytes and the individual monocyte subtypes were
not affected by risk-genotype or phenotype (data not shown). CD14+ CD16- classical
Fig 2. Genotype dependent CD40 protein expression in peripheral B-lymphocyte subsets of MS patients and healthy controls. B lymphocyte
subsets from healthy controls (n = 86) and MS patients (n = 21) were identified by flow cytometry (A) and CD40 expression determined relative to an isotype
control (relative fluorescence intensity; RFI). Regulatory B cells were identified as CD19+CD38hiCD24hi (data not shown) (B). Association of rs1883832
genotype with CD40 expression in healthy controls (CC = 49, CT = 27, TT = 10) was examined in total B lymphocytes (C), naïve B-lymphocytes (D) and
classical memory B-lymphocytes (E), and in total B lymphocytes (F), naïve B lymphocytes (G) and classical B lymphocytes (H) of MS patients (CC = 12,
CT = 7, TT = 2). p values were determined by Mann-Whitney U test comparison of each group.
doi:10.1371/journal.pone.0127080.g002
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Fig 3. CD40 protein is under- expressed in B lymphocytes of MS patients. B lymphocyte subsets from healthy controls (n = 86) and MS patients (n = 24)
were identified by flow cytometry and CD40 expression determined relative to an isotype control (relative fluorescence intensity; RFI). Surface levels of CD40
were compared in total B-lymphocytes (A), B lymphocytes from rs1883832 CC individuals (B; n = 49 healthy controls, n = 12 MS patients), naïve B
lymphocytes (C), classical memory B lymphocytes (D) and IgMmemory B lymphocytes (E). P-values were determined using Mann—Whitney test.
doi:10.1371/journal.pone.0127080.g003
Fig 4. Genotype dependent CD40 protein expression in peripheral monocyte subsets of MS patients and healthy controls.Monocyte subsets were
identified by flow cytometry (A) and CD40 expression determined relative to an isotype control (relative fluorescence intensity; RFI) (B). Association of
rs1883832 genotype with CD40 expression was examined in classical CD14+CD16- (C), intermediate CD14+CD16+ (D) and non-classical CD14lowCD16+
+ monocytes (E) from healthy controls (CC = 49, CT = 27, TT = 10), and classical CD14+CD16- (F), intermediate CD14+CD16+ (G) and non-classical
CD14lowCD16++ monocytes (H) fromMS patients (CC = 12, CT = 7, TT = 2). P—values were determined by Mann-Whitney test.
doi:10.1371/journal.pone.0127080.g004
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monocytes expressed significantly lower levels of CD40 on the cell surface compared to the in-
termediate and non-classical monocyte subtypes in both healthy controls and MS (Fig 4B).
CD40 expression is not significantly affected by genotype or phenotype
in monocyte subsets
There was no significant difference in the level of CD40 expression in monocytes between MS
and controls (Fig 4C). In addition, there were no genotype-dependent effects on CD40 expres-
sion in healthy controls (Fig 4D).
The CD40 MS risk-allele is under expressed in dendritic cell subsets
Dendritic cells are the major antigen presenting cells. However, DCs from whole blood are not
typical of those in the secondary lymphoid organs and tissues, which are thought to drive T cell
activation in autoimmune diseases [29]. Fortunately DCs representative of tissue DCs can be
differentiated from monocytes, and have been verified as inflammatory (DC1) or tolerogenic
(DC2) on the basis morphology and IL12p40 and IL10 mRNA and protein expression [23].
These DCs express much higher levels of CD40 mRNA and protein than monocytes and B
cells (Fig 5). In these cells, CD40 expression was genotype dependent, with reduced expression
of the risk allele at the mRNA level in DC2s (Fig 6A, p< 0.011) and at the protein level in both
DC phenotypes (Fig 6B; p< 0.0047, DC1s; p< 0.0043, DC2s).
Lower proportions of the full-length isoform from the CD40 MS risk-allele
Greater splicing of the CD40 risk allele was evident with a lower percentage of the full length
mRNA isoform expressed in DCs and monocytes compared to expression levels in DC carrying
at least one protective allele (Fig 7; p< 0.0020, monocytes; p< 0.0014, DC1s; p< 0.0026,
DC2s). A similar trend was evident in whole blood in healthy controls (CC> CT; p< 0.13)
and MS (CT> TT; p< 0.056; Fig 8). As CD40 isoform usage was affected by the MS risk geno-
type, we sought common SNPs located between exon 4 and exon 8 that might affect splicing.
All SNPs identified as inherited in strong LD with rs6074022 in the 1000 genome project and
located between exon 4 and exon 8 (rs73115010, rs66815221, rs73622651, rs6074028,
Fig 5. CD40 expression is higher in differentiated dendritic cell subsets.CD40 expression was determined in freshly purified immune cell subsets (B
cells, monocytes) or in vitro differentiated dendritic cells (DC1, DC2) from healthy controls. Gene expression by RT-PCR (A; n = 49) and relative fluorescence
intensity (RFI) by flow cytometry (B; n = 41) are shown; *significantly different frommonocytes and DCs; **significantly different from B cells and monocytes
(A) or frommonocytes (B); p < 0.05 by Mann-Whitney test.
doi:10.1371/journal.pone.0127080.g005
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Fig 6. The CD40 risk allele is under expressed in dendritic cell subsets. Association of rs1883832 genotype with CD40 expression was determined in in
vitro differentiated dendritic cells (DC1, DC2) from healthy controls (non-carriers, CC, or carriers, CT/TT, of the risk allele). Gene expression by RT-PCR (A;
n = 49) and relative fluorescence intensity (RFI) by flow cytometry (B; n = 41) are shown; p values by Mann-Whitney test.
doi:10.1371/journal.pone.0127080.g006
Fig 7. Lower proportions of the full-length isoform expressed from the CD40 risk allele in monocytes
and dendritic cells. Association of rs1883832 genotype (CC, TC, TT) with the proportion of full-length
isoform of CD40 (%FL) expressed in in vitro differentiated dendritic cells (DC1, DC2) from healthy controls
(n = 49). Molar ratios of isoforms were quantitated by RT-PCR and amplification of a region spanning CD40
exon 4–10, followed by electrophoretic separation and fluorescent detection (Bioanalyzer, Agilent); p values
by Mann-Whitney test.
doi:10.1371/journal.pone.0127080.g007
CD40 and Multiple Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0127080 June 11, 2015 9 / 14
rs3746821, rs11569333) were intronic and in regions unlikely to affect splicing, as assessed
with the Human Splicing Finder tool [30]. The minor allele frequency of the exonic SNPs from
exon 4 to exon 8 was less than 4%, so unlikely to be driving the genotype association. This in-
cluded 3 SNPS (rs369901991, rs371997367, rs144600981) calculated in Ensembl to potentially
affect splicing.
Discussion
In this study we show an MS risk genotype-dependent reduction of CD40 cell-surface protein
in B-lymphocytes and polarised dendritic cells. This is paralleled by lower levels of CD40
mRNA production from the risk genotype in these cells, and an increased relative proportion
of isoforms encoding the secreted form of CD40. In addition, and for the first time, we show
that the level of CD40 protein expression is significantly reduced in B-lymphocytes isolated
fromMS patients compared to healthy controls, independent of risk genotype. This is consis-
tent with our previous findings that whole blood CD40 mRNA was reduced in carriers of the
risk genotype, and that the effect of genotype on expression was enhanced in MS [20]. These
results also point towards additional factors leading to the down-regulation of CD40 protein
expression in MS patients besides CD40 genotype, and thus implicate lower cell surface CD40
protein expression in the complex pathogenesis of MS.
However, our findings are in contrast to previous studies that have shown no difference in
either the mRNA or protein levels of CD40 expression between MS patients and controls
[21,22]. These previous cohorts were of varying disease phenotype, including patients in the
progressive phase of disease, varying relapse status and with a wider range of disease duration
[21,22] possibly capturing, at least for those with relapse, a more inflammatory state with con-
comitantly higher CD40 expression, thus masking the reduced CD40 expression we observed
in our cohort of patients with stable relapsing-remitting disease.
The opposite genetic association of CD40 rs1883832 with increased susceptibility to MS,
but with protection from RA and GD are intriguing and point to distinct roles for CD40 in the
pathogenic processes in these autoimmune diseases. Our studies here and previously [20], as
well as studies in RA and GD [5,6] have consistently demonstrated an association of the T allele
with reduced CD40 expression. The association of protection from RA and GD with lower
Fig 8. Proportions of the full-length isoform expressed from the CD40 risk allele in whole blood. Association of rs1883832 genotype (CC, TC, TT) with
the proportion of full-length isoform of CD40 (%FL) expressed in whole blood from healthy controls (A; n = 38) and MS (B; n = 32). Molar ratios of isoforms
were quantitated by RT-PCR and amplification of a region spanning CD40 exon 4–10, followed by electrophoretic separation and fluorescent detection
(Bioanalyzer, Agilent). Trends were observed for CC > CT in controls (p < 0.13) and for CT > TT in MS, (p < 0.056); p values by Mann-Whitney test.
doi:10.1371/journal.pone.0127080.g008
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expression of a T cell activation gene fits with a primarily costimulatory role of CD40 support-
ing the autoimmune inflammatory process, and supported by animal models in which CD40
inhibition reduces inflammation. In contrast, the association of protection fromMS with
higher expression of CD40 may suggest that these inflammatory processes are protective in
MS, and/or that thymic tolerogenic processes mediated by CD40 are of greater importance in
protection fromMS than CD40-mediated autoimmune inflammatory processes are in disease
initiation or propagation.
It is intriguing that Epstein Bar virus (EBV), long implicated in MS pathogenesis [31], en-
codes a homologue of human CD40, This protein is expressed in infected B cells, and constitu-
tively signals, promoting B cell proliferation [32]. Relative susceptibility to EBV may be
dependent on competition between human and EBV CD40/CD40L signaling. Notably though,
a genome wide association study of SNPs with EBNA-1 antibody levels did not implicate CD40
[33]. This would suggest any CD40 genotype associations with EBV susceptibility, or EBV con-
tribution to MS, may be independent of EBNA-1 antibody levels.
Tolerogenic responses mediated by CD40 stimulation include naïve B lymphocyte- mediat-
ed stimulation of T cells leading to the expansion of regulatory T cells [34]. In addition, naïve B
lymphocytes (and regulatory B cells found within the naïve B lymphocyte pool) have been
shown to produce regulatory cytokines such as IL-10 upon stimulation with CD40L [35]. In
addition to these peripheral immunoregulatory mechanisms, cortical and medullary thymic
epithelial cells (cTECS and mTECs) express functional CD40 [36], which has been shown to be
essential for the establishment of the mTEC microenvironment leading to tolerance to self-an-
tigens [37]. The role of Vitamin D/UVR driven immunomodulation [38,39], mediated by
APCs, may also provide an additional link between reduced CD40 expression and increased
MS risk, with under-expression of CD40 by DCs leading to the failure of the protective effects
of increased Vitamin D/UVR.
A decrease in CD40 expression by these cell types could plausibly lead to a failure of toler-
ance/immunomodulatory mechanisms mediated by CD40 stimulation, and by extension, a
failure of protection from the development of MS in subsequent years.
While CD40 expression is known to be increased in thyroid tissue in GD [40], no examina-
tion has been made of either the genotype-dependent effects of CD40 expression in GD pa-
tients, or CD40 expression by peripheral immune cells in the context of disease. In SLE, a risk-
genotype dependent correlation in CD40 expression level in B lymphocytes has been identified,
present in both patients and healthy controls [13], however there is no apparent genotype-in-
dependent effect in CD40 expression levels between SLE patients and healthy controls. Cer-
tainly, the genotype-independent decrease in CD40 expression by peripheral immune cells in
MS is a unique and novel finding, and leads to many questions as to the reasons for this de-
crease, as well as the subsequent effects. Is this decrease a result of “exhaustion” of CD40 ex-
pression in MS similar to that of CD8 “exhaustion” in chronic viral infection [41], or is it a
result of homeostatic down-regulation in the context of inflammation?
The absence of a known genetic variant in the exon 4 to 8 region that would drive the ob-
served risk genotype dependent splicing differences could indicate that either a novel variant
exists which has yet to be included in the 1000genome and ensemble databases, or that mRNA
splicing is regulated from outside this region, as has been described for other genes [42]. Al-
though increased production of soluble isoforms could be expected to reduce signaling through
reducing both cell surface expression and offering alternative ligand binding, soluble receptors
have also been shown to potentially increase signaling through increasing the half-life of li-
gands (e.g. potentially for soluble CD40L) [43], and further work is required to ascertain if sol-
uble CD40 levels are indeed relatively increased in MS patients, as these data suggest. The net
effect of the risk haplotype on expression may actually a be gain of function.
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Further work is needed to understand the consequences of decreased CD40 expression on B
lymphocyte and dendritic cells in antiviral/immunoregulatory functions in demyelinating dis-
ease, and what drives reduced expression of CD40 in B lymphocytes in established MS. Defin-
ing the genotype-independent but disease-dependent changes in B lymphocyte and dendritic
cell CD40 levels identified in this study could uncover protective roles for CD40 in MS that
fundamentally distinguish its pathogenesis from that of other autoimmune diseases.
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